Denosumab: What’s New?

César E. Bogado(Universidad del Salvador), José Zanchetta(Universidad del Salvador), María Belén Zanchetta(Universidad del Salvador), Juan A. Boailchuk(Instituto de Diagnóstico e Investigaciones Metabólicas), Fabio Massari(Universidad del Salvador)

Current Osteoporosis Reports

December 3, 2010

10.1007/s11914-010-0040-1

Cited by 6

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis

|New England Journal of Medicine|2001|4.6k

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

|New England Journal of Medicine|2009|3.5k

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

|New England Journal of Medicine|2014|1.2k

Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial

|Journal of Bone and Mineral Research|2008|508

Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial

|Arthritis & Rheumatism|2009|497